Related Experiment Videos
Insights
Daily aspirin significantly reduced myocardial infarction in men with unstable angina. Further research is needed to confirm findings and explore other treatments for this condition.
Area of Science:
- Cardiology
- Clinical Trials
- Pharmacology
Background:
- Unstable angina poses significant risks for myocardial infarction and mortality.
- Existing randomized trials for unstable angina treatments are limited in scope and size.
- Aortocoronary bypass surgery and heparin therapy have shown mixed or flawed results.
Purpose of the Study:
- To evaluate the efficacy of daily aspirin in reducing myocardial infarction and mortality in men with unstable angina.
- To assess the current evidence for various unstable angina therapies.
Main Methods:
- A randomized, double-blind clinical trial involving 1266 men with unstable angina.
- Participants received either 324 mg of aspirin daily or a placebo for 12 weeks.
- Literature review of existing randomized trials for other unstable angina treatments.
Main Results:
- Daily aspirin (324 mg) for 12 weeks resulted in a 51% reduction in myocardial infarction incidence (p = .001).
- Data suggested a similar reduction in mortality associated with aspirin treatment.
- Randomized trials of aortocoronary bypass surgery did not demonstrate decreased mortality or infarction rates.
Conclusions:
- Aspirin therapy demonstrates significant efficacy in reducing myocardial infarction in unstable angina patients.
- Current evidence for other treatments like heparin, nitrates, beta-blockers, calcium blockers, fibrinolytic therapy, and coronary angioplasty is inadequate.
- Well-controlled clinical trials are necessary to establish optimal management strategies for unstable angina.
Abstract:
A randomized, double-blind clinical trial in 1266 men with unstable angina showed that 324 mg of aspirin daily for 12 weeks reduced the incidence of myocardial infarction by 51% (p = .001), and the data suggested a similar reduction in mortality. The only other therapy for unstable angina that has been studied in randomized trials of adequate size to evaluate mortality and rate of infarction is aortocoronary bypass surgery. Results with heparin therapy have been encouraging, but the studies in which this drug has been tested have been flawed. Nitrates, beta-blockers, calcium blockers, fibrinolytic therapy, and coronary angioplasty have not been adequately evaluated. Randomized trials of aortocoronary bypass surgery have not demonstrated decreased mortality or rates of myocardial infarction in patients with unstable angina. Although surgical techniques have improved since these trials were conducted, medical management has also improved. Mortality and infarct rate in patients with unstable angina are now lower than in the early 1970s. New well-controlled clinical trials are needed.